In 2020, Lee et al. [64] examined with an ML-based approach the [18F]fluciclovine PET images of a cohort of 251 PCa patients with suspected BCR following definitive primary therapy, to automatically identify “normal” patients (no disease recurrence) and “abnormal” patients (locoregional or distant recurrence). The gene discussed is BCR; the disease is posterior cortical atrophy.